logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Unresponsiveness to AmBisome in some Sudanese patients with kala-azar

Mueller M, Ritmeijer KKD, Balasegaram M, Koummuki Y, Santana MR,  et al.
2007-01-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
2007-01-01 • Transactions of the Royal Society of Tropical Medicine and Hygiene
In Sudan, two treatments are currently registered for visceral leishmaniasis: sodium stibogluconate (SSG) as first line and liposomal amphotericin B (AmBisome) as second line. We present...
Journal Article
|
Research

A comparison of liposomal Amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan

Mueller M, Balasegaram M, Koummuki Y, Ritmeijer KKD, Santana MR,  et al.
2006-10-01 • Journal of Antimicrobial Chemotherapy
2006-10-01 • Journal of Antimicrobial Chemotherapy
OBJECTIVES: Little is known about the treatment of visceral leishmaniasis (VL) in pregnancy, especially in resource-poor settings. We present a series of pregnant women with VL treated w...
Journal Article
|
Research

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Hailu ADE, Musa AM, Wasunna M, Balasegaram M, Yifru S,  et al.
2010-10-26 • PLOS Neglected Tropical Diseases
2010-10-26 • PLOS Neglected Tropical Diseases
Visceral leishmaniasis (VL) is a major health problem in developing countries. The untreated disease is fatal, available treatment is expensive and often toxic, and drug resistance is in...